8 results about "Myofibrosis" patented technology

The application belongs to the field of biological medicine, and relates to an anti-mouse integrin CD103 nanobody and application. The anti-mouse integrin CD103 nanobody comprises three complementarity determining regions CDR1, CDR2 and CDR3; wherein the amino acid sequence of CDR1 is a sequence or a high homology sequence shown in one of SEQ ID NO:1 to SEQ ID NO:4, the amino acid sequence of CDR2 is a sequence or a high homology sequence shown in one of SEQ ID NO:5 to SEQ ID NO:8, and the amino acid sequence of CDR3 is a sequence or a high homology sequence shown in one of SEQ ID NO:9 to SEQ ID NO:12. The application relates to the anti-mouse integrin CD103 nanobody and a preparation method thereof 18 The F-CYNB nanobody probe can realize targeted imaging of myocardial fibrosis, immune imaging of mouse tumors, and prediction of the effect of tumor immunotherapy.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition for improving heart failure and its preparation method. The traditional Chinese medicine composition for improving heart failure comprises the following raw materials in parts by weight: astragaloside A 4-7 parts, arctiin 8-12 parts, citrinin 3-6 parts, and perilla lactone 2-4 parts. Experimental results show that taking the traditional Chinese medicine composition for improving heart failure prepared according to this invention has the effects of tonifying heart qi, warming yang and tonifying kidney, promoting blood circulation and detoxifying, and reducing swelling and promoting diuresis, thereby effectively improving cardiac function, inhibiting excessive activation of the RAAS system, reducing myocardial damage and myocardial fibrosis, and significantly alleviating heart failure symptoms. Furthermore, the traditional Chinese medicine composition provided by this invention has precise formulation, few toxic side effects, high safety, and broad application prospects.

The application relates to application of miRNA and / or a miRNA agonist in preparation of a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, and belongs to the technical field of biological medicine. The medicine is administered through skeletal muscle injection, is secreted to a circulation system after expression on the skeletal muscle, is delivered to heart tissue by taking extracellular vesicles as carriers, and thus regulates myocardial cell functions. According to the animal model verification result, the miRNA can be delivered to the heart by the extracellular vesicles secreted by the skeletal muscle through injection of the medicine into the skeletal muscle, the expression level of the miRNA in the I / RI heart is significantly increased, the myocardial infarction area is effectively reduced, myocardial cell apoptosis is inhibited, myocardial fibrosis is reduced, and heart function is improved, a brand-new intervention strategy is provided for treatment of myocardial ischemia-reperfusion injury and related heart diseases, and a brand-new idea is opened up for research and development of heart failure treatment medicines.

The present application relates to the technical field of medicine, and particularly relates to application of OpiCa1 or a nano-liposome thereof in preparation of a drug for treating and / or preventing myocardial fibrosis related diseases. The present application is found that OpiCa1 and the nano-liposome thereof can inhibit myocardial fibrosis and improve myocardial remodeling in the myocardial remodeling period after myocardial infarction, and have a good antagonistic effect on myocardial infarction and subsequent heart failure. Further transcriptomic analysis shows that in the process of treating myocardial infarction in mice, OpiCa1 and the nano-liposome thereof can inhibit fibrosis and improve myocardial remodeling by possibly participating in extracellular matrix degradation in myocardial remodeling and fibrosis pathways (such as TGF-beta signaling pathway), so as to achieve the purpose of relieving myocardial infarction deterioration.

The present application relates to the technical field of genetic engineering, in particular to a kind of gene medicine for treating PNPLA2 mutation arrhythmogenic cardiomyopathy and its preparation method and application.The effective component of gene medicine provided in the present application includes shuttle plasmid;The shuttle plasmid includes AAV9 carrier and PNPLA2 gene.The present application delivers normal PNPLA2 gene by AAV9 carrier, repairs the lipid metabolism disorder caused by mutation, reduces the fat deposition in myocardium, and then improves the pathological changes of ACM.By restoring the function of PNPLA2 gene, the process of myocardial fibrosis can be effectively inhibited, and the heart function can be improved.The present application uses myocardial specific promoter cTnT to ensure that PNPLA2 gene is only expressed in myocardium, so as to improve the targeting of gene therapy, and avoid the side effects caused by systemic expression.This strategy can effectively reduce the side effects of gene therapy, and ensure the accuracy and safety of treatment.

This invention discloses the pharmaceutical applications of UGDH in the prevention and treatment of myocardial infarction, belonging to the field of biomedical technology. This invention is the first to demonstrate that UDP-glucose dehydrogenase (UGDH) plays a key regulatory role in the pathological process of myocardial infarction, with significantly upregulated UGDH expression in a myocardial infarction model. Fibroblast-specific knockdown of UGDH significantly improves cardiac function in mice after myocardial infarction, reduces the infarct area, and inhibits myocardial fibrosis and excessive fibroblast activation; overexpression of UGDH significantly worsens the aforementioned pathological phenotypes. This invention clarifies that UGDH can serve as a novel target for the prevention, treatment, and auxiliary diagnosis of myocardial infarction, providing a new direction for the development of gene therapy drugs for myocardial infarction.

The application discloses application of SGC707 in preparation of anti-myocardial fibrosis drugs and belongs to the technical field of medicines.The experiment verifies that SGC707 can significantly reduce myocardial tissue collagen deposition of mice caused by ISO, obviously relieve the increase of mRNA expression levels of alpha-SMA, TGF-beta, PRMT3, p53 and PAI-1 caused by ISO, has the function of slowing down myocardial fibrosis, has important clinical guiding significance for treating myocardial fibrosis and provides a new way for exploring development of low-toxicity and high-efficiency anti-myocardial fibrosis drugs.

The present application relates to the technical field of biological medicine, in particular to a nucleic acid molecule for treating myocardial infarction, a vector and a pharmaceutical composition and application thereof, the IFIT1 mRNA targeting inhibitor is a nucleic acid molecule which can reduce the expression level of IFIT1 mRNA in mesenchymal stem cells, the nucleic acid molecule can be siRNA, shRNA or antisense oligonucleotide (ASO), the target sequence of the siRNA, shRNA or ASO is shown as SEQ ID NO: 1. The present application proposes the use of IFIT1 translation inhibition for MI treatment and promotion of myocardial regeneration, enhances MSC differentiation into myocardial cells by silencing IFIT1 mRNA, reduces myocardial fibrosis by IFIT1 inhibitor, induces MSC to produce spontaneously beating muscle-like cells, improves heart function, thereby treating myocardial infarction, and opens a new direction for myocardial infarction treatment.